Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 6Carcinoma, Hepatocellular 2Tuberous Sclerosis 1Recurrence 1Prostate Cancer Patients 1Neoplasms 1Lymphangioleiomyomatosis 1Glioma 1Glioblastoma 1Disease 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

Sirolimus 10Everolimus 6Imatinib Mesylate 2temsirolimus 1saracatinib 1nintedanib 1carbon-11 acetate 1Valproic Acid 1Urination 1Sugars 1Simvastatin 1Resveratrol 1Respiratory Function Tests 1Phlebotomy 1Octreotide 1Loratadine 1Letrozole 1Immunoglobulin G 1Hydroxychloroquine 1Glutamine 1Genetic Testing 1Doxycycline 1Disulfides 1Cetuximab 1Celecoxib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × carbon-11 acetate × Clear all
NCT05467397 2026-01-21

Feasibility of [11C]Acetate-PET in LAM and TSC

Brigham and Women's Hospital

Phase 1/2 Active not recruiting
7 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡